Recent advances in the management of AL Amyloidosis

British Journal of Haematology

Volumn 172, Issue 2, 2016, Pages 170-186

  Kastritis, Efstathios ^a   Dimopoulos, Meletios A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Heart failure; Immunoglobulins; Light chains; Mass spectrometry; Monoclonal antibodies

Indexed keywords

IMMUNOGLOBULIN LIGHT CHAIN; MELPHALAN; MYELOABLATIVE AGENT;

AMYLOIDOSIS; DRUG EFFECTS; HUMAN; IMMUNOLOGY; METABOLISM; PATHOLOGY; PLASMA CELL; PROCEDURES; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

AMYLOIDOSIS; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MELPHALAN; MYELOABLATIVE AGONISTS; PLASMA CELLS; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84954025980     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13805     Document Type: Article

References (105)

1. Abraham, R.S., Ballman, K.V., Dispenzieri, A., Grill, D.E., Manske, M.K., Price-Troska, T.L., Paz, N.G., Gertz, M.A. & Fonseca, R. (2005) Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis. Blood, 105, 794-803.
2. Bochtler, T., Hegenbart, U., Heiss, C., Benner, A., Moos, M., Seckinger, A., Pschowski-Zuck, S., Kirn, D., Neben, K., Bartram, C.R., Ho, A.D., Goldschmidt, H., Hose, D., Jauch, A. & Schonland, S.O. (2011) Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14). Blood, 117, 3809-3815.
3. Bochtler, T., Hegenbart, U., Kunz, C., Benner, A., Seckinger, A., Dietrich, S., Granzow, M., Neben, K., Goldschmidt, H., Ho, A.D., Hose, D., Jauch, A. & Schonland, S.O. (2014) Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone. Amyloid, 21, 9-17.
4. Bochtler, T., Hegenbart, U., Kunz, C., Granzow, M., Benner, A., Seckinger, A., Kimmich, C., Goldschmidt, H., Ho, A.D., Hose, D., Jauch, A. & Schonland, S.O. (2015) Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. Journal of Clinical Oncology, 33, 1371-1378.
5. Bodin, K., Ellmerich, S., Kahan, M.C., Tennent, G.A., Loesch, A., Gilbertson, J.A., Hutchinson, W.L., Mangione, P.P., Gallimore, J.R., Millar, D.J., Minogue, S., Dhillon, A.P., Taylor, G.W., Bradwell, A.R., Petrie, A., Gillmore, J.D., Bellotti, V., Botto, M., Hawkins, P.N. & Pepys, M.B. (2010) Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature, 468, 93-97.
6. Brambilla, F., Lavatelli, F., Di Silvestre, D., Valentini, V., Rossi, R., Palladini, G., Obici, L., Verga, L., Mauri, P. & Merlini, G. (2012) Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood, 119, 1844-1847.
7. Brenner, D.A., Jain, M., Pimentel, D.R., Wang, B., Connors, L.H., Skinner, M., Apstein, C.S. & Liao, R. (2004) Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circulation Research, 94, 1008-1010.
8. Bryce, A.H., Ketterling, R.P., Gertz, M.A., Lacy, M., Knudson, R.A., Zeldenrust, S., Kumar, S., Hayman, S., Buadi, F., Kyle, R.A., Greipp, P.R., Lust, J.A., Russell, S., Rajkumar, S.V., Fonseca, R. & Dispenzieri, A. (2009) Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica, 94, 380-386.
9. Cibeira, M.T., Sanchorawala, V., Seldin, D.C., Quillen, K., Berk, J.L., Dember, L.M., Segal, A., Ruberg, F., Meier-Ewert, H., Andrea, N.T., Sloan, J.M., Finn, K.T., Doros, G., Blade, J. & Skinner, M. (2011) Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood, 118, 4346-4352.
10. Cibeira, M.T., Oriol, A., Lahuerta, J.J., Mateos, M.V., de la Rubia, J., Hernandez, M.T., Granell, M., Fernandez de Larrea, C., San Miguel, J.F. & Blade, J. (2015) A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis. British Journal of Haematology, 170, 804-813.
11. Cohen, A.D., Scott, E.C., Liedtke, M., Kaufman, J.L., Landau, H., Vesole, D.H., Gomes, C.L., Gasparetto, C., Lentzsch, S., Rosenzweig, M., Sanchorawala, V., Smith, D.D., Comenzo, R.L. & Durie, B.G.M. (2014) A phase I dose-escalation study of carfilzomib in patients with previously-treated systemic light-chain (AL) Amyloidosis. Blood, 124, 4741.
12. Dember, L.M., Hawkins, P.N., Hazenberg, B.P., Gorevic, P.D., Merlini, G., Butrimiene, I., Livneh, A., Lesnyak, O., Puechal, X., Lachmann, H.J., Obici, L., Balshaw, R., Garceau, D., Hauck, W. & Skinner, M. (2007) Eprodisate for the treatment of renal disease in AA amyloidosis. New England Journal of Medicine, 356, 2349-2360.
13. Dey, B.R., Chung, S.S., Spitzer, T.R., Zheng, H., Macgillivray, T.E., Seldin, D.C., McAfee, S., Ballen, K., Attar, E., Wang, T., Shin, J., Newton-Cheh, C., Moore, S., Sanchorawala, V., Skinner, M., Madsen, J.C. & Semigran, M.J. (2010) Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure. Transplantation, 90, 905-911.
14. Dingli, D., Tan, T.S., Kumar, S.K., Buadi, F.K., Dispenzieri, A., Hayman, S.R., Lacy, M.Q., Gastineau, D.A., Hogan, W.J. & Gertz, M.A. (2010) Stem cell transplantation in patients with autonomic neuropathy due to primary (AL) amyloidosis. Neurology, 74, 913-918.
15. Dinner, S., Witteles, W., Afghahi, A., Witteles, R., Arai, S., Lafayette, R., Schrier, S.L. & Liedtke, M. (2013) Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement. Haematologica, 98, 1593-1599.
16. Diomede, L., Rognoni, P., Lavatelli, F., Romeo, M., del Favero, E., Cantu, L., Ghibaudi, E., di Fonzo, A., Corbelli, A., Fiordaliso, F., Palladini, G., Valentini, V., Perfetti, V., Salmona, M. & Merlini, G. (2014) A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis. Blood, 123, 3543-3552.
17. Dispenzieri, A., Gertz, M.A., Kyle, R.A., Lacy, M.Q., Burritt, M.F., Therneau, T.M., Greipp, P.R., Witzig, T.E., Lust, J.A., Rajkumar, S.V., Fonseca, R., Zeldenrust, S.R., McGregor, C.G. & Jaffe, A.S. (2004) Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. Journal of Clinical Oncology, 22, 3751-3757.
18. Dispenzieri, A., Lacy, M.Q., Zeldenrust, S.R., Hayman, S.R., Kumar, S.K., Geyer, S.M., Lust, J.A., Allred, J.B., Witzig, T.E., Rajkumar, S.V., Greipp, P.R., Russell, S.J., Kabat, B. & Gertz, M.A. (2007) The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood, 109, 465-470.
19. Dispenzieri, A., Dingli, D., Kumar, S.K., Rajkumar, S.V., Lacy, M.Q., Hayman, S., Buadi, F., Zeldenrust, S., Leung, N., Detweiler-Short, K., Lust, J.A., Russell, S.J., Kyle, R.A. & Gertz, M.A. (2010) Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. American Journal of Hematology, 85, 757-759.
20. Dispenzieri, A., Buadi, F., Laumann, K., LaPlant, B., Hayman, S.R., Kumar, S.K., Dingli, D., Zeldenrust, S.R., Mikhael, J.R., Hall, R., Rajkumar, S.V., Reeder, C., Fonseca, R., Bergsagel, P.L., Stewart, A.K., Roy, V., Witzig, T.E., Lust, J.A., Russell, S.J., Gertz, M.A. & Lacy, M.Q. (2012) Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood, 119, 5397-5404.
21. Dispenzieri, A., Seenithamby, K., Lacy, M.Q., Kumar, S.K., Buadi, F.K., Hayman, S.R., Dingli, D., Litzow, M.R., Gastineau, D.A., Inwards, D.J., Micallef, I.N., Ansell, S.M., Johnston, P.B., Porrata, L.F., Patnaik, M.M., Hogan, W.J. & Gertz, M.A. (2013) Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center. Bone Marrow Transplantation, 48, 1302-1307.
22. Dubrey, S.W., Reece, D.E., Sanchorawala, V., Hegenbart, U., Merlini, G., Palladini, G., Fermand, J.P., Vescio, R.A., Blade, J., Heffner, L.T., Hassoun, H., Liu, X., Enny, C., Ramaswami, P., Elsayed, Y., Van De Velde, H., Mortimer, S., Cakana, A. & Comenzo, R.L. (2011) Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects. QJM, 104, 957-970.
23. Fernandez de Larrea, C., Verga, L., Morbini, P., Klersy, C., Lavatelli, F., Foli, A., Obici, L., Milani, P., Capello, G.L., Paulli, M., Palladini, G. & Merlini, G. (2015) A practical approach to the diagnosis of systemic amyloidoses. Blood, 125, 2239-2244.
24. Foli, A., Palladini, G., Caporali, R., Verga, L., Morbini, P., Obici, L., Russo, P., Sarais, G., Donadei, S., Montecucco, C. & Merlini, G. (2011) The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 62 patients. Amyloid, 18, 80-82.
25. Gertz, M.A. & Kyle, R.A. (1988) Hepatic amyloidosis (primary [AL], immunoglobulin light chain): the natural history in 80 patients. The American Journal of Medicine, 85, 73-80.
26. Gertz, M.A., Li, C.Y., Shirahama, T. & Kyle, R.A. (1988) Utility of subcutaneous fat aspiration for the diagnosis of systemic amyloidosis (immunoglobulin light chain). Archives of Internal Medicine, 148, 929-933.
27. Gertz, M.A., Kyle, R.A. & Greipp, P.R. (1989) The plasma cell labeling index: a valuable tool in primary systemic amyloidosis. Blood, 74, 1108-1111.
28. Gertz, M.A., Lacy, M.Q., Dispenzieri, A., Ansell, S.M., Elliott, M.A., Gastineau, D.A., Inwards, D.J., Micallef, I.N., Porrata, L.F., Tefferi, A. & Litzow, M.R. (2004) Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplantation, 34, 1025-1031.
29. Gertz, M.A., Comenzo, R., Falk, R.H., Fermand, J.P., Hazenberg, B.P., Hawkins, P.N., Merlini, G., Moreau, P., Ronco, P., Sanchorawala, V., Sezer, O., Solomon, A. & Grateau, G. (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. American Journal of Hematology, 79, 319-328.
30. Gertz, M.A., Lacy, M.Q., Lust, J.A., Greipp, P.R., Witzig, T.E. & Kyle, R.A. (2008) Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis. Haematologica, 93, 1402-1406.
31. Gertz, M.A., Lacy, M.Q., Dispenzieri, A., Hayman, S.R., Kumar, S.K., Dingli, D., Ansell, S.M., Gastineau, D.A., Inwards, D.J., Johnston, P.B., Litzow, M.R., Micallef, I.N., Porrata, L.F., Leung, N., Hogan, W.J. & Buadi, F.K. (2010) Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. Leukemia & Lymphoma, 51, 2181-2187.
32. Gertz, M.A., Lacy, M.Q., Dispenzieri, A., Kumar, S.K., Dingli, D., Leung, N., Hogan, W.J., Buadi, F.K. & Hayman, S.R. (2013) Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplantation, 48, 557-561.
33. Gertz, M.A., Landau, H.J., Comenzo, R., Seldin, D.C., Weiss, B.M., Zonder, J.A., Walling, J., Kinney, G., Koller, M. & Liedtke, M. (2015) Cardiac and renal biomarker responses in a phase 1/2 study of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction. Journal of Clinical Oncology (ASCO Meeting Abstracts), 33, 8514.
34. Gillmore, J.D., Tennent, G.A., Hutchinson, W.L., Gallimore, J.R., Lachmann, H.J., Goodman, H.J., Offer, M., Millar, D.J., Petrie, A., Hawkins, P.N. & Pepys, M.B. (2010) Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. British Journal of Haematology, 148, 760-767.
35. Gray Gilstrap, L., Niehaus, E., Malhotra, R., Ton, V.K., Watts, J., Seldin, D.C., Madsen, J.C. & Semigran, M.J. (2014) Predictors of survival to orthotopic heart transplant in patients with light chain amyloidosis. The Journal of Heart and Lung Transplantation, 33, 149-156.
36. Guan, J., Mishra, S., Qiu, Y., Shi, J., Trudeau, K., Las, G., Liesa, M., Shirihai, O.S., Connors, L.H., Seldin, D.C., Falk, R.H., MacRae, C.A. & Liao, R. (2014) Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity. EMBO Molecular Medicine, 6, 1493-1507.
37. Hawkins, P.N., Lavender, J.P. & Pepys, M.B. (1990) Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. New England Journal of Medicine, 323, 508-513.
38. Hegenbart, U., Bochtler, T., Dreger, P., Kimmich, R., Ziehl, R., Goldschmidt, H., Ho, A. & Schonland, S. (2014) Long-term results of 174 patients with systemic AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation: a single center experience. Haematologica, 99, S1305.
39. Jaccard, A., Moreau, P., Leblond, V., Leleu, X., Benboubker, L., Hermine, O., Recher, C., Asli, B., Lioure, B., Royer, B., Jardin, F., Bridoux, F., Grosbois, B., Jaubert, J., Piette, J.C., Ronco, P., Quet, F., Cogne, M. & Fermand, J.P. (2007) High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. New England Journal of Medicine, 357, 1083-1093.
40. Jaccard, A., Comenzo, R.L., Hari, P., Hawkins, P.N., Roussel, M., Morel, P., Macro, M., Pellegrin, J.L., Lazaro, E., Mohty, D., Mercie, P., Decaux, O., Gillmore, J., Lavergne, D., Bridoux, F., Wechalekar, A.D. & Venner, C.P. (2014) Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica, 99, 1479-1485.
41. Kastritis, E., Anagnostopoulos, A., Roussou, M., Toumanidis, S., Pamboukas, C., Migkou, M., Tassidou, A., Xilouri, I., Delibasi, S., Psimenou, E., Mellou, S., Terpos, E., Nanas, J. & Dimopoulos, M.A. (2007) Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica, 92, 1351-1358.
42. Kastritis, E., Roussou, M., Michael, M., Gavriatopoulou, M., Michalis, E., Migkou, M., Delimpasi, S., Kyrtsonis, M.C., Gogos, D., Liapis, K., Charitaki, E., Repousis, P., Terpos, E. & Dimopoulos, M.A. (2010a) High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients. British Journal of Haematology, 150, 587-591.
43. Kastritis, E., Wechalekar, A.D., Dimopoulos, M.A., Merlini, G., Hawkins, P.N., Perfetti, V., Gillmore, J.D. & Palladini, G. (2010b) Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. Journal of Clinical Oncology, 28, 1031-1037.
44. Kastritis, E., Terpos, E., Roussou, M., Gavriatopoulou, M., Pamboukas, C., Boletis, I., Marinaki, S., Apostolou, T., Nikitas, N., Gkortzolidis, G., Michalis, E., Delimpasi, S. & Dimopoulos, M.A. (2012) A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood, 119, 5384-5390.
45. Kastritis, E., Leleu, X., Arnulf, B., Zamagni, E., Mollee, P., Cibeira, M.T., Schönland, S.O., Moreau, P., Hajek, R., Jaccard, A., Nicolas-Virelizier, E., Filshie, R., Augustson, B., Mateos, M.-V., Milani, P., Dimopoulos, M.A., Hachulla, E., Fermand, J.-P., Foli, A., Palumbo, A., Sonneveld, P., Johnsen, H.E., Merlini, G. & Palladini, G. (2014) A randomized phase III trial of melphalan and dexamethasone (MDex) versus bortezomib, melphalan and dexamethasone (BMDex) for untreated patients with AL amyloidosis. Blood, 124, 35-35.
46. Kastritis, E., Gavriatopoulou, M., Dimopoulos, M.A., Eleutherakis-Papaiakovou, E., Kanellias, N., Roussou, M., Pamboucas, C., Toumanidis, S.T. & Terpos, E. (2015a) Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging. Blood Cancer Journal, 5, e319.
47. Kastritis, E., Roussou, M., Gavriatopoulou, M., Migkou, M., Kalapanida, D., Pamboucas, C., Kaldara, E., Ntalianis, A., Psimenou, E., Toumanidis, S.T., Tasidou, A., Terpos, E. & Dimopoulos, M.A. (2015b) Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies. American Journal of Hematology, 90, E60-E65.
48. Kourelis, T.V., Kumar, S.K., Gertz, M.A., Lacy, M.Q., Buadi, F.K., Hayman, S.R., Zeldenrust, S., Leung, N., Kyle, R.A., Russell, S., Dingli, D., Lust, J.A., Lin, Y., Kapoor, P., Rajkumar, S.V., McCurdy, A. & Dispenzieri, A. (2013) Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. Journal of Clinical Oncology, 31, 4319-4324.
49. Kourelis, T.V., Kumar, S.K., Go, R.S., Kapoor, P., Kyle, R.A., Buadi, F.K., Gertz, M.A., Lacy, M.Q., Hayman, S.R., Leung, N., Dingli, D., Lust, J.A., Lin, Y., Zeldenrust, S.R., Rajkumar, S.V. & Dispenzieri, A. (2014) Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. American Journal of Hematology, 89, 1051-1054.
50. Kumar, S., Dispenzieri, A., Lacy, M.Q., Hayman, S.R., Buadi, F.K., Colby, C., Laumann, K., Zeldenrust, S.R., Leung, N., Dingli, D., Greipp, P.R., Lust, J.A., Russell, S.J., Kyle, R.A., Rajkumar, S.V. & Gertz, M.A. (2012a) Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. Journal of Clinical Oncology, 30, 989-995.
51. Kumar, S.K., Hayman, S.R., Buadi, F.K., Roy, V., Lacy, M.Q., Gertz, M.A., Allred, J., Laumann, K.M., Bergsagel, L.P., Dingli, D., Mikhael, J.R., Reeder, C.B., Stewart, A.K., Zeldenrust, S.R., Greipp, P.R., Lust, J.A., Fonseca, R., Russell, S.J., Rajkumar, S.V. & Dispenzieri, A. (2012b) Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood, 119, 4860-4867.
52. Landau, H., Hassoun, H., Rosenzweig, M.A., Maurer, M., Liu, J., Flombaum, C., Bello, C., Hoover, E., Riedel, E., Giralt, S. & Comenzo, R.L. (2013) Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia, 27, 823-828.
53. Liao, R., Jain, M., Teller, P., Connors, L.H., Ngoy, S., Skinner, M., Falk, R.H. & Apstein, C.S. (2001) Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation, 104, 1594-1597.
54. Lin, G., Dispenzieri, A., Kyle, R., Grogan, M. & Brady, P.A. (2013) Implantable cardioverter defibrillators in patients with cardiac amyloidosis. Journal of Cardiovascular Electrophysiology, 24, 793-798.
55. Lock, R.J., Saleem, R., Roberts, E.G., Wallage, M.J., Pesce, T.J., Rowbottom, A., Cooper, S.J., McEvoy, E.D., Taylor, J.L. & Basu, S. (2013) A multicentre study comparing two methods for serum free light chain analysis. Annals of Clinical Biochemistry, 50, 255-261.
56. Loustaud-Ratti, V.R., Cypierre, A., Rousseau, A., Yagoubi, F., Abraham, J., Fauchais, A.L., Carrier, P., Lefebvre, A., Bordessoule, D., Vidal, E., Sautereau, D. & Jaccard, A. (2011) Non-invasive detection of hepatic amyloidosis: FibroScan, a new tool. Amyloid, 18, 19-24.
57. Mahmood, S., Gilbertson, J.A., Rendell, N., Whelan, C.J., Lachmann, H.J., Wechalekar, A.D., Hawkins, P.N. & Gillmore, J.D. (2014) Two types of amyloid in a single heart. Blood, 124, 3025-3027.
58. Mereles, D., Buss, S.J., Hardt, S.E., Hunstein, W. & Katus, H.A. (2010) Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis. Clinical Research in Cardiology, 99, 483-490.
59. Merlini, G. & Bellotti, V. (2003) Molecular mechanisms of amyloidosis. New England Journal of Medicine, 349, 583-596.
60. Merlini, G., Comenzo, R.L., Seldin, D.C., Wechalekar, A. & Gertz, M.A. (2014a) Immunoglobulin light chain amyloidosis. Expert Review of Hematology, 7, 143-156.
61. Merlini, G., Sanchorawala, V., Jeffrey, Z.A., Kukreti, V., Schoenland, S.O., Jaccard, A., Dispenzieri, A., Cohen, A.D., Berg, D., Yuan, Z., Hui, A.-M., Giovanni, P. & Comenzo, R.L. (2014b) Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL). Blood, 124, 3450-3450.
62. Mikhael, J.R., Schuster, S.R., Jimenez-Zepeda, V.H., Bello, N., Spong, J., Reeder, C.B., Stewart, A.K., Bergsagel, P.L. & Fonseca, R. (2012) Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood, 119, 4391-4394.
63. Milani, P., Rosin, M.V., Foli, A. & Merlini, G. (2013) High-dose pomalidomide and dexamethasone induce rapid responses in patients with AL amyloidosis exposed to alkylators, immune modulatory drugs, and proteasome inhibitors. Blood, 122, 288-288.
64. Mishra, S., Guan, J., Plovie, E., Seldin, D.C., Connors, L.H., Merlini, G., Falk, R.H., MacRae, C.A. & Liao, R. (2013) Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. American Journal of Physiology - Heart and Circulatory Physiology, 305, H95-H103.
65. Monis, G.F., Schultz, C., Ren, R., Eberhard, J., Costello, C., Connors, L., Skinner, M. & Trinkaus-Randall, V. (2006) Role of endocytic inhibitory drugs on internalization of amyloidogenic light chains by cardiac fibroblasts. American Journal of Pathology, 169, 1939-1952.
66. Moreau, P., Jaccard, A., Benboubker, L., Royer, B., Leleu, X., Bridoux, F., Salles, G., Leblond, V., Roussel, M., Alakl, M., Hermine, O., Planche, L., Harousseau, J.L. & Fermand, J.P. (2010) Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood, 116, 4777-4782.
67. Palladini, G., Malamani, G., Co, F., Pistorio, A., Recusani, F., Anesi, E., Garini, P. & Merlini, G. (2001) Holter monitoring in AL amyloidosis: prognostic implications. Pacing and Clinical Electrophysiology, 24, 1228-1233.
68. Palladini, G., Perfetti, V., Obici, L., Caccialanza, R., Semino, A., Adami, F., Cavallero, G., Rustichelli, R., Virga, G. & Merlini, G. (2004) Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood, 103, 2936-2938.
69. Palladini, G., Perfetti, V., Perlini, S., Obici, L., Lavatelli, F., Caccialanza, R., Invernizzi, R., Comotti, B. & Merlini, G. (2005) The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood, 105, 2949-2951.
70. Palladini, G., Dispenzieri, A., Gertz, M.A., Kumar, S., Wechalekar, A., Hawkins, P.N., Schonland, S., Hegenbart, U., Comenzo, R., Kastritis, E., Dimopoulos, M.A., Jaccard, A., Klersy, C. & Merlini, G. (2012a) New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. Journal of Clinical Oncology, 30, 4541-4549.
71. Palladini, G., Schonland, S.O., Milani, P., Kimmich, C., Foli, A., Bochtler, T., Merlini, G. & Hegenbart, U. (2012b) Treatment of AL amyloidosis with bendamustine. Blood (ASH Annual Meeting Abstracts), 120, 4057.
72. Palladini, G., Hegenbart, U., Milani, P., Kimmich, C., Foli, A., Ho, A.D., Vidus Rosin, M., Albertini, R., Moratti, R., Merlini, G. & Schonland, S. (2014a) A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood, 124, 2325-2332.
73. Palladini, G., Milani, P., Foli, A., Obici, L., Lavatelli, F., Nuvolone, M., Caccialanza, R., Perlini, S. & Merlini, G. (2014b) Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica, 99, 743-750.
74. Palladini, G., Milani, P., Foli, A., Vidus Rosin, M., Basset, M., Lavatelli, F., Nuvolone, M., Obici, L., Perlini, S. & Merlini, G. (2014c) Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients. Leukemia, 28, 2311-2316.
75. Palladini, G., Sachchithanantham, S., Milani, P., Gillmore, J., Foli, A., Lachmann, H., Basset, M., Hawkins, P., Merlini, G. & Wechalekar, A.D. (2015) A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood, 126, 612-615.
76. Parmar, S., Kongtim, P., Champlin, R., Dinh, Y., Elgharably, Y., Wang, M., Bashir, Q., Shah, J.J., Shah, N., Popat, U., Giralt, S.A., Orlowski, R.Z. & Qazilbash, M.H. (2014) Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up. Bone Marrow Transplantation, 49, 1036-1041.
77. Perfetti, V., Palladini, G., Casarini, S., Navazza, V., Rognoni, P., Obici, L., Invernizzi, R., Perlini, S., Klersy, C. & Merlini, G. (2012) The repertoire of lambda light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44. Blood, 119, 144-150.
78. Pinney, J.H., Lachmann, H.J., Bansi, L., Wechalekar, A.D., Gilbertson, J.A., Rowczenio, D., Sattianayagam, P.T., Gibbs, S.D., Orlandi, E., Wassef, N.L., Bradwell, A.R., Hawkins, P.N. & Gillmore, J.D. (2011) Outcome in renal Al amyloidosis after chemotherapy. Journal of Clinical Oncology, 29, 674-681.
79. Prokaeva, T., Spencer, B., Kaut, M., Ozonoff, A., Doros, G., Connors, L.H., Skinner, M. & Seldin, D.C. (2007) Soft tissue, joint, and bone manifestations of AL amyloidosis: clinical presentation, molecular features, and survival. Arthritis & Rheumatology, 56, 3858-3868.
80. Quarta, C.C., Buxbaum, J.N., Shah, A.M., Falk, R.H., Claggett, B., Kitzman, D.W., Mosley, T.H., Butler, K.R., Boerwinkle, E. & Solomon, S.D. (2015) The amyloidogenic V122I transthyretin variant in elderly black Americans. New England Journal of Medicine, 372, 21-29.
81. Rapezzi, C., Quarta, C.C., Guidalotti, P.L., Pettinato, C., Fanti, S., Leone, O., Ferlini, A., Longhi, S., Lorenzini, M., Reggiani, L.B., Gagliardi, C., Gallo, P., Villani, C. & Salvi, F. (2011) Role of (99 m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. Journal of the American College of Cardiology - Cardiovascular Imaging, 4, 659-670.
82. Reece, D.E., Hegenbart, U., Sanchorawala, V., Merlini, G., Palladini, G., Blade, J., Fermand, J.P., Hassoun, H., Heffner, L., Vescio, R.A., Liu, K., Enny, C., Esseltine, D.L., van de Velde, H., Cakana, A. & Comenzo, R.L. (2011) Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood, 118, 865-873.
83. Richards, D.B., Cookson, L.M., Berges, A.C., Barton, S.V., Lane, T., Ritter, J.M., Fontana, M., Moon, J.C., Pinzani, M., Gillmore, J.D., Hawkins, P.N. & Pepys, M.B. (2015) Therapeutic clearance of amyloid by antibodies to serum amyloid P component. New England Journal of Medicine, 373, 1106-1114.
84. Rubinow, A., Skinner, M. & Cohen, A.S. (1981) Digoxin sensitivity in amyloid cardiomyopathy. Circulation, 63, 1285-1288.
85. Sanchorawala, V. (2014) High dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis. Hematology/oncology Clinics of North America, 28, 1131-1144.
86. Sanchorawala, V., Wright, D.G., Rosenzweig, M., Finn, K.T., Fennessey, S., Zeldis, J.B., Skinner, M. & Seldin, D.C. (2007) Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood, 109, 492-496.
87. Sattianayagam, P.T., Gibbs, S.D., Pinney, J.H., Wechalekar, A.D., Lachmann, H.J., Whelan, C.J., Gilbertson, J.A., Hawkins, P.N. & Gillmore, J.D. (2010) Solid organ transplantation in AL amyloidosis. American Journal of Transplantation, 10, 2124-2131.
88. Sayed, R.H., Rogers, D., Khan, F., Wechalekar, A.D., Lachmann, H.J., Fontana, M., Mahmood, S., Sachchithanantham, S., Patel, K., Hawkins, P.N., Whelan, C.J. & Gillmore, J.D. (2015) A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis. European Heart Journal, 36, 1098-1105.
89. Schonland, S.O., Hegenbart, U., Bochtler, T., Mangatter, A., Hansberg, M., Ho, A.D., Lohse, P. & Rocken, C. (2012) Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood, 119, 488-493.
90. Shi, J., Guan, J., Jiang, B., Brenner, D.A., Del Monte, F., Ward, J.E., Connors, L.H., Sawyer, D.B., Semigran, M.J., Macgillivray, T.E., Seldin, D.C., Falk, R. & Liao, R. (2010) Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proceedings of the National Academy of Sciences of the United States of America, 107, 4188-4193.
91. Soares, S.M., Fervenza, F.C., Lager, D.J., Gertz, M.A., Cosio, F.G. & Leung, N. (2008) Bleeding complications after transcutaneous kidney biopsy in patients with systemic amyloidosis: single-center experience in 101 patients. American Journal of Kidney Diseases, 52, 1079-1083.
92. Swiecicki, P.L., Edwards, B.S., Kushwaha, S.S., Dispenzieri, A., Park, S.J. & Gertz, M.A. (2013) Left ventricular device implantation for advanced cardiac amyloidosis. The Journal of Heart and Lung Transplantation, 32, 563-568.
93. Tang, W., McDonald, S.P., Hawley, C.M., Badve, S.V., Boudville, N., Brown, F.G., Clayton, P.A., Campbell, S.B., de Zoysa, J.R. & Johnson, D.W. (2013) End-stage renal failure due to amyloidosis: outcomes in 490 ANZDATA registry cases. Nephrology Dialysis Transplantation, 28, 455-461.
94. Teng, J., Turbat-Herrera, E.A. & Herrera, G.A. (2014) An animal model of glomerular light-chain-associated amyloidogenesis depicts the crucial role of lysosomes. Kidney International, 86, 738-746.
95. Venner, C.P., Lane, T., Foard, D., Rannigan, L., Gibbs, S.D., Pinney, J.H., Whelan, C.J., Lachmann, H.J., Gillmore, J.D., Hawkins, P.N. & Wechalekar, A.D. (2012) Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood, 119, 4387-4390.
96. Venner, C.P., Gillmore, J.D., Sachchithanantham, S., Mahmood, S., Lane, T., Foard, D., Rannigan, L., Gibbs, S.D., Pinney, J.H., Whelan, C.J., Lachmann, H.J., Hawkins, P.N. & Wechalekar, A.D. (2014) A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis. Leukemia, 28, 2304-2310.
97. Vrana, J.A., Gamez, J.D., Madden, B.J., Theis, J.D., Bergen, H.R. 3rd & Dogan, A. (2009) Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood, 114, 4957-4959.
98. Wall, J.S., Kennel, S.J., Williams, A., Richey, T., Stuckey, A., Huang, Y., Macy, S., Donnell, R., Barbour, R., Seubert, P. & Schenk, D. (2012) AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils. PLoS ONE, 7, e52686.
99. Wang, A.K., Fealey, R.D., Gehrking, T.L. & Low, P.A. (2008) Patterns of neuropathy and autonomic failure in patients with amyloidosis. Mayo Clinic Proceedings, 83, 1226-1230.
100. Ward, J.E., Ren, R., Toraldo, G., Soohoo, P., Guan, J., O'Hara, C., Jasuja, R., Trinkaus-Randall, V., Liao, R., Connors, L.H. & Seldin, D.C. (2011) Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis. Blood, 118, 6610-6617.
101. Wechalekar, A.D., Goodman, H.J., Lachmann, H.J., Offer, M., Hawkins, P.N. & Gillmore, J.D. (2007) Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood, 109, 457-464.
102. Wechalekar, A.D., Lachmann, H.J., Goodman, H.J., Bradwell, A., Hawkins, P.N. & Gillmore, J.D. (2008) AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood, 112, 4009-4016.
103. Wechalekar, A.D., Schonland, S.O., Kastritis, E., Gillmore, J.D., Dimopoulos, M.A., Lane, T., Foli, A., Foard, D., Milani, P., Rannigan, L., Hegenbart, U., Hawkins, P.N., Merlini, G. & Palladini, G. (2013) A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood, 121, 3420-3427.
104. Wechalekar, A., Whelan, C., Sachchithanantham, S., Fontana, M., Mahmood, S., Foard, D., Lane, T., Lachmann, H.J., Gillmore, J.D. & Hawkins, P.N. (2014) A matched case control study of doxycycline added to chemotherapy for reducing early mortality in patients with advanced cardiac AL amyloidosis from the alchemy study cohort. Blood, 124, 3485-3485.
105. Wechalekar, A.D., Gillmore, J.D., Bird, J., Cavenagh, J., Hawkins, S., Kazmi, M., Lachmann, H.J., Hawkins, P.N. & Pratt, G. (2015) Guidelines on the management of AL amyloidosis. British Journal of Haematology, 168, 186-206.